Polymer-drug conjugates: Present state of play and future perspectives

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1316-1322

  Pang, Xin ^a   Du, Hong Liang ^a   Zhang, Hai Qun ^a   Zhai, Ying Jie ^a   Zhai, Guang Xi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AD 70; AP 5280; AP 5346; ATORVASTATIN; CHITOSAN; CRLX 101; CT 2106; CYCLODEXTRIN CAMPTOTHECIN CONJUGATE; DE 310; DELIMOTECAN; DEXTRAN DOXORUBICIN CONJUGATE; DEXTRAN EXATECAN CONJUGATE; DOXORUBICIN; ETIRINOTECAN PEGOL; FCE 28068; FIRTECAN PEGOL; FLEXIMER CAMPTOTHECIN CONJUGATE; HEPARIN; HYALURONIC ACID; MACROGOL; NALOXEGOL; NKTR 105; PACLITAXEL POLIGLUMEX; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE DOXORUBICIN DEXAMETHASON CONJUGATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE DOXORUBICIN GEMCITABINE CONJUGATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE] DOXORUBICIN AMINOGLUTETHIMIDE CONJUGATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE] DOXORUBICIN CONJUGATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE] PACLITAXOL ALENDRONATE CONJUGATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE] PLATINUM CONJUGATE; POLYETHYLENE GLYCOL DOCETAXEL CONJUGATE; POLYGLUTAMIC ACID CAMPTOTHECIN CONJUGATE; POLYMER; POLYSACCHARIDE; PROLINDAC; SALICYLIC ACID; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XMT 1001; DRUG; DRUG CARRIER;

ADVANCED CANCER; BIODEGRADABILITY; BLEEDING; BREAST METASTASIS; CIRCULATION TIME; COLON CANCER; COLORECTAL CANCER; CONJUGATE; CONSTIPATION; COVALENT BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; LIVER TOXICITY; LUNG CANCER; LUNG SMALL CELL CANCER; MOLECULAR WEIGHT; NEUTROPENIA; OPIOID INDUCED CONSTIPATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; STOMACH CANCER; TECHNOLOGY; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CHEMISTRY; DRUG DESIGN; SOLUBILITY;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84889086366     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.09.007     Document Type: Review

References (52)

1. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
2. R. Haag, and F. Kratz Polymer therapeutics: concepts and applications Angew. Chem. Int. Ed. 45 2006 1198 1215
3. H. Jatzkewitz Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline) Z. Naturforsch. 10b 1955 27 31
4. W. Regelson Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy J. Bioact. Compat. Polymers 1 1986 84 106
5. H. Ringsdorf Structure and properties of pharmacologically active polymers J. Polym. Sci. Polym. Symp. 51 1975 135 153
6. R. Duncan, and J. Kopecek Soluble synthetic polymers as potential drug carriers Adv. Polymer Sci. 57 1984 51 101
7. R. Duncan Drug-polymer conjugates: potential for improved chemotherapy Anti-Cancer Drugs 3 1992 175 210
8. R. Duncan Preclinical evaluation of polymer-bound doxorubicin J. Control. Release 19 1992 331 346
9. H. Maeda Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
10. R. Gaspar, and R. Duncan Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics Adv. Drug Del. Rev. 61 2009 1220 1231
11. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2009 688 701
12. G. Pasut, and F.M. Veronese State of the art in PEGylation: the great versatility achieved after forty years of research J. Control. Release 161 2012 461 472
13. J.M. Harris, and R.B. Chess Effect of PEGylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
14. P. Wonganan, and M.A. Croyle PEGylated adenoviruses: from mice to monkeys Viruses 2 2010 468 502
15. W. Li Current drug research on PEGylation with small molecular agents Prog. Poly. Sci. 38 2013 421 444
16. B. Obereigner Preparation of polymerizable derivatives of N-(4-aminobenzenesulfonyl)-n′-butylurea J. Polym. Sci. Polym. Symp. 66 1979 41 52
17. P.A. Vasey Phase I clinical and pharmacokinetic study of PK1 N-(2-Hydroxypropyl)methacrylamide copolymer doxorubicin: first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin. Cancer Res. 5 1999 83 94
18. E. Markovsky Administration, distribution, metabolism and elimination of polymer therapeutics J. Control. Release 161 2012 446 460
19. T. Etrych HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity J. Control. Release 164 2012 346 354
20. H. Pan Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy Macromol. Biosci. 13 2013 155 160
21. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 2009 1203 1213
22. E. Jäger Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester J. Control. Release 165 2013 153 161
23. E.J. Oh Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives J. Control. Release 141 2010 2 12
24. G.B. Jiang Stable nanomicelles based on chitosan derivative: in vitro antiplatelet aggregation and adhesion properties Carbohydr. Polym. 88 2012 232 238
25. M. Anwar Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats Eur. J. Pharm. Sci. 44 2011 241 249
26. R. Zeng Effect of bond linkage on in vitro drug release and anti-HIV activity of chitosan-stavudine conjugates Macromol. Res. 20 2012 358 365
27. T.H. Tran Microfluidic approach for highly efficient synthesis of heparin-based bioconjugates for drug delivery Lab. Chip. 12 2012 589 594
28. S. Danhauser-Ried Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) Invest. New Drugs 11 1993 187 195
29. O. Soepenberg Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors Clin. Cancer Res. 11 2005 703 711
30. C. Young CRLX101 (formerly IT-101) - a novel nanopharmaceutical of camptothecin in clinical development Curr. Bioact. Compd. 7 2011 8 14
31. S. Jung Anti-AIDS active polyrotaxane-AZT conjugates with bioactive bulky stoppers and their nanoparticles J. Polym. Sci. Part A: Polym. Chem. 50 2012 4895 4901
32. G. Perera Novel pectin-4-aminothiophenole conjugate microparticles for colon-specific drug delivery J. Control. Release 145 2010 240 246
33. R.I. Pinhassi Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells Biomacromolecules 11 2010 294 303
34. F. Greco Polysialic acid as a drug carrier: evaluation of a new polysialic acid-epirubicin conjugate and its comparison against established drug carriers Polym. Chem. 6 2013 1600 1609
35. F. Li Self-assembled nanoparticles from folate-decorated maleilated pullulan-doxorubicin conjugate for improved drug delivery to cancer cells J. Polym. Int. 62 2013 165 171
36. X. Cai Synthesis and anaerobic biodegradation of indomethacin-conjugated cellulose ethers used for colon-specific drug delivery Bioresource Technol. 100 2009 4164 4170
37. L. Kaminskas Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers Mol. Pharm. 6 2009 1190 1204
38. J. Ishizaki Selective drug delivery to bone using acidic oligopeptides J. Bone Miner. Metab. 27 2009 1 8
39. T. Takahashi-Nishioka Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs Curr. Drug Discov. Technol. 5 2008 39 48
40. M.P. Melancon, and C. Li Multifunctional synthetic poly(K-glutamic acid)-based cancer therapeutic and imaging agents Mol. Imaging 10 2011 28 42
41. F. Canal Polymer-drug conjugates as nano-sized medicines Curr. Opin. Chem. Biol. 22 2011 894 900
42. A. Eldar-Boock Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel Biomaterials 32 2011 3862 3874
43. Van, S. et al. (2008) Nitto Denko. Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs, US 20080279778
44. B.K. Nanjwade Dendrimers: emerging polymers for drug-delivery systems Eur. J. Pharm. Sci. 38 2009 185 196
45. Y. Li A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas Biomaterials 33 2012 3899 3908
46. N. Larson, and H. Ghandehari Polymeric conjugates for drug delivery Chem. Mater. 24 2012 840 853
47. S. Mignani Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview Adv. Drug Deliv. Rev 2013 doi: 10.1016/j. addr.2013.01.001 (in press)
48. K. Jain Dendrimer toxicity: let's meet the challenge Int. J. Pharm. 394 2010 122 142
49. A.R. Menjoge Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications Drug Discov. Today 15 2010 171 185
50. R. Duncan, and M.J. Vicent Polymer therapeutics-prospects for 21st century: the end of the beginning Adv. Drug Deliv. Rev. 65 2013 60 70
51. B. Apostolovic Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers Biomacromolecules 11 2010 1187 1195
52. C.A. Blencowe Self-immolative linkers in polymeric delivery systems Polym. Chem. 2 2011 773 790